Back to search results

Multi-Cancer Detection Observational Study

This study is looking at how Multi-Cancer Detection (MCD) tests, which are designed to find many types of cancer, are being used in real-world medical care. We want to understand both how these tests are used and what their effects are. You may be able to join if you have a Mayo Clinic medical record number, are at least 21 years old, and have recently had or are scheduled to have an MCD test ordered by your doctor. We will be collecting blood samples and asking you to complete surveys about your attitudes and beliefs regarding MCD testing. The study will look at the financial and psychological impact of MCD testing, and how often positive results lead to further action, over a period of up to 5 years.

Study design
This is an observational study, meaning researchers will watch and collect information without giving any specific treatment. The study plans to enroll 500 participants.
What's involved
You will provide up to two blood samples, one initially and another 25-45 days later. You will also complete surveys about your attitudes and beliefs regarding MCD testing.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years to assess the financial impact, positive actionable MCD results, and psychological impact of MCD testing.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06962995

Multi-Cancer Detection Observational Cohort Study

Recruiting
Not specifiedAges 21+Observational
Mayo Clinic
~500 participants
Updated 2026-04-06 on ClinicalTrials.gov
What's tested:Blood SampleSurveys

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Financial impact of MCD testing
Measured over Up to 5 years
+3 more outcomes measured

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

3 sites across 3 states
Arizona1
Florida1
Minnesota1

Study leadership

  • Jewel Samadder, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has Mayo Clinic medical record number
Has undergone (within last 6 months) or scheduled to undergo a multi-cancer detection test (MCD) as ordered by provider
Able to provide informed consent
≥ 21 years old
Ability to provide blood sample

Exclusion

Individuals who have situations that would limit compliance with the study requirements
Institutionalized (i.e. Federal Medical Prison)
Known pregnancy (self-reported)
Currently undergoing active cancer treatment other than adjuvant hormone therapy
Invasive cancer diagnosis within the last 3 years

What this trial measures

  • Financial impact of MCD testingUp to 5 years

    Assessed by types of diagnostic studies ordered as a result of positive MCD test results (e.g., to establish or rule out a cancer diagnosis).

  • Positive actionable MCD resultsUp to 5 years

    Assessed by the number of participants who receive positive MCD results

  • Psychological Impact of MCD TestingBaseline (after receiving MCD results)

    Assessed with the Multidimensional Impact of Cancer Risk Assessment (Adapted MICRA), which asks participants to evaluate their response to MCD test results over the past week. The MICRA consists of 20 items answered on a 4-point scale (Never, Rarely, Sometimes, Often). Higher scores generally indicate higher levels of distress or psychological impact.

  • Change in Patient Satisfaction with MCD TestBaseline; After receiving MCD results (up to 5 years)

    Participants will complete a 3-question survey, "Satisfaction with the Multi-Cancer Detection Test." Items are answered on a 5-point scale (not at all, a little, somewhat, very, extremely).